Background: Major depressive disorder (MDD) with concurrent anxiety symptoms may signal a difficult-to-treat patient. Brexpiprazole is a serotonin-dopamine activity modulator: a partial agonist at 5-HT 1A and dopamine D 2 receptors at similar potency, and an antagonist at 5-HT 2A and noradrenaline alpha 1B/2C receptors. The objective of this Phase IIIb study was to explore effectiveness, safety, and tolerability of brexpiprazole adjunctive to antidepressant (ADT) monotherapy in patients with MDD and anxiety symptoms (NCT02013531).
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Fifth Edition (DSM-5), which included the addition of criteria for a "with Anxious Distress" specifier for MDD (American Psychiatric Association, 2013) .
Evidence-based guidance on treatment strategies for patients with MDD and concurrent anxiety symptoms is scarce. Several large studies have reported that patients with MDD and anxiety symptoms have poorer treatment outcomes than patients who are not anxious (Wiethoff et al., 2010; Farabaugh et al., 2012; Fava et al., 2008; Ionescu et al., 2014) . Although monotherapy with antidepressant treatments (ADTs) can be effective in treating MDD with anxiety symptoms, patients may be less likely to experience sustained response or remission (Ionescu et al., 2014) . Subgroup analyses of short-term, larger studies have indicated that augmentation with an antipsychotic is an effective strategy in the treatment of MDD with anxiety symptoms (Bandelow et al., 2014; Trivedi et al., 2008) . Pooled analysis from two double-blind, placebo-controlled studies in patients with MDD and inadequate response to ADTs demonstrated that augmentation with aripiprazole improved Montgomery-Åsberg Depression Rating Scale (MADRS) total score in a subgroup with baseline Hamilton Rating Scale for Depression (HAM-D) anxiety/somatization factor score ≥ 7 (Trivedi et al., 2008) . Quetiapine extended-release (XR) augmentation has also been reported to improve MADRS total score in subgroups of patients with MDD and inadequate response to ADTs, with anxious depression defined as baseline HAM-D anxiety/somatization factor score ≥ 7, and alternatively as baseline Hamilton Rating Scale for Anxiety (HAM-A) ≥ 20 (Bandelow et al., 2014) .
Brexpiprazole is a serotonin-dopamine activity modulator that is a partial agonist at serotonin 5-HT 1A and dopamine D 2 receptors at similar potency, and an antagonist at 5-HT 2A and noradrenaline alpha 1B/2C receptors (Maeda et al., 2014) . In two pivotal Phase III, double-blind, placebo-controlled studies, brexpiprazole 2 and 3 mg day −1 + ADT significantly improved the MADRS total score versus placebo over 6 weeks in patients with MDD and inadequate response to ADTs (Thase et al., 2015a (Thase et al., , 2015b . The tolerability profile observed with brexpiprazole in these short-term studies was consistent with its receptor pharmacology. Brexpiprazole has low intrinsic activity at D 2 receptors (Maeda et al., 2014) , which may reduce the potential for activating side effects.
The objective of this Phase IIIb study (ClinicalTrials.gov NCT02013531) was to explore the effectiveness, safety, and tolerability of brexpiprazole + ADT in patients with MDD and anxiety symptoms who had an inadequate response to their current ADT.
| METHODS

| Study participants
Study participants selected for this study were male or female out- (Sheehan et al., 1998) 
| Study design
This was an open-label, flexible-dose study conducted in 12 cent- ) was added to the current ADT, and a 30-day follow-up phase (Fig. 1) .
The study was conducted in compliance with the International Conference on Harmonization Good Clinical Practice guidelines. The protocol was approved by an institutional review board or independent ethics committee at each center. All participants provided informed consent to participate and none required surrogate consent.
| Efficacy assessments
Efficacy was assessed using the MADRS (Montgomery & Åsberg, 1979) ; Clinical Global Impression-Severity of illness scale (CGI-S) (Guy, 1976) ; HAM-A; Clinical Global Impression-Improvement scale (CGI-I) (Guy, 1976) ; HAM-D-17; Kellner Symptom Questionnaire (KSQ) (Kellner, 1987) ; Sheehan Disability Scale (SDS) (Sheehan, Harnett-Sheehan, & Raj, 1996) ; Massachusetts General HospitalCognitive and Physical Functioning Questionnaire (MGH-CPFQ) (Fava et al., 2009) ; and Barratt Impulsiveness Scale 11-item (BIS-11) (Patton, Stanford, & Barratt, 1995) . MADRS, CGI-S, HAM-A, and CGI-I were completed at weekly intervals from baseline to Week 6; all other assessments were conducted at baseline and Week 6 or study discontinuation. In addition, HAM-D-17 and HAM-A were carried out at screening and baseline to confirm eligibility.
| Safety and tolerability assessments
Safety and tolerability assessments were adverse events (AEs), clinical laboratory tests, body weight, vital signs, ECGs, SimpsonAngus Scale (SAS) (Simpson & Angus, 1970) , Abnormal Involuntary Movement Scale (AIMS) (Guy, 1976) , Barnes Akathisia Rating Scale (BARS) (Barnes, 1989) , and Columbia Suicide Severity Rating Scale (C-SSRS) (Posner et al., 2011) .
| Statistical analysis
No formal sample size calculations were performed. The safety population comprised all participants who took at least one dose of brexpiprazole, while the efficacy population included only participants in the safety population with an efficacy assessment both at baseline and on at least one occasion postbaseline.
The primary efficacy endpoint was change from baseline at Week 6 in MADRS total score. Other efficacy endpoints included change from baseline at Week 6 in CGI-S score, HAM-A total score, HAM-D-17 total score, KSQ total and symptom subscale scores, SDS mean and individual item scores, MGH-CPFQ total score, and BIS-11 total score, and CGI-I score at Week 6. Responder rate was defined as the proportion of participants with ≥50% reduction from baseline in MADRS total score at Week 6; or a CGI-I score of 1 or 2 at Week 6. Remission rate was defined as the proportion of participants with MADRS total score ≤10 and a reduction from baseline of ≥50% in MADRS total score at Week 6.
Analysis of the primary efficacy endpoint was based on actual observations recorded at each visit, and no missing data were imputed (observed cases). A mixed model repeated measures (MMRM) analysis was fitted with an unstructured variance covariance structure, in which change from baseline in MADRS total score was the dependent variable. The model included fixed class effect terms for visit, baseline score, and the interaction term of score-by-visit. Point estimates and associated two-sided 95% confidence intervals (CIs) were calculated.
The null hypothesis of zero mean change from baseline at Week 6 was tested at a significance level of .05. As this was an exploratory trial, no methods to control type I error rate were warranted. Change from baseline at Week 6 in CGI-S score and HAM-A total score were analyzed in the same way as the primary efficacy endpoint. The other efficacy endpoints were summarized using last-observation-carriedforward data.
Changes from baseline at last visit were reported for fasting meta- , and was increased to 1 and 2 mg day −1 at Weeks 1 and 2, respectively. Thereafter, the dose could be decreased at any time to 1 mg day −1 or increased at study visits to 3 mg day −1
, as required. All participants discontinued brexpiprazole at the end of the treatment phase, and were contacted by telephone to monitor safety at the end of the 30-day follow-up phase. ADT, antidepressant; ET, early termination; MDD, major depressive disorder; SNRI, serotonin noradrenaline reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor 3 | RESULTS
| Participants
We enrolled 37 participants, of whom 32 (86.5%) completed the study. Of the five participants who discontinued the study, three were lost to follow-up, one withdrew consent, and one became pregnant and was discontinued. All 37 participants were included in the safety population; one participant was excluded from the efficacy population because they did not have an efficacy assessment both at baseline and on at least one occasion postbaseline.
Participants who completed the study received brexpiprazole at a mean dose of 2.1 mg day −1 in addition to their current ADT.
In the safety population, mean (SD) age was 45.7 (15.2) years and mean (SD) body mass index was 29.9 (6.7) kg m −2 (Table 1 ). There were more female than male participants (female: 26/37, 70.3%), and most participants were Caucasian (26/37, 70.3%).
Mean (SD) duration of the current episode of MDD was 13.6
(18.0) months, while the median was 8.9 months. Most of the participants (32, 86.5%) had experienced recurrent episodes of depression.
During the current episode, 32 participants (86.5%) reported an inadequate response to one ADT, while five participants (13.5%) had an inadequate response to at least two ADTs. None of the participants had been treated with an antipsychotic during the current episode.
Baseline depression and anxiety rating scale scores confirmed that the participant population had moderate-to-severe depression and anxiety symptoms (Table 1) . ). Three participants (8.1%) took lorazepam during the 6-week treatment phase: two of these participants received 0.5 mg four times per week for 3 and 4 weeks, respectively, and one participant took a single dose of 0.5 mg.
| Efficacy
At CGI-I score at Week 6 was 1.9 (1.1).
Mean HAM-D-17 total score improved from baseline at Week 6, as did MGH-CPFQ total score and BIS-11 total score (Table 2) . Mean KSQ total score improved over the 6-week treatment period; reductions were seen in all symptom subscale scores: anxiety, depression, somatic symptoms, and anger-hostility (Table 2) . Mean (SD) SDS mean score improved by 3.6 (2.6) points from baseline at Week 6, while individual item scores for social life, family life, and home responsibilities, and work and school life also improved at Week 6 (Fig. 3) .
As defined by CGI-I, 75% (27/36) of the participants met the threshold for response at Week 6 (95% CI: 57.8%, 87.9% 
| Safety and tolerability
Treatment-emergent adverse events (TEAEs) were reported by 75.7% (28/37) of the participants (Table 3) ; however, none of the TEAEs resulted in discontinuation of brexpiprazole. The most frequently reported TEAEs were increased appetite, diarrhea, dry mouth, and dizziness. Most of the TEAEs were considered by the investigators to be mild or moderate in severity, while two were considered to be severe (arthralgia; neck pain). One participant experienced a serious AE (pneumonia) after completion of brexpiprazole treatment.
T A B L E 1 Demographics and baseline clinical characteristics (safety population)
Brexpiprazole, n = 37 
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EPS-related TEAEs were reported by 8.1% (3/37) of the participants; these were two reports of akathisia and one of extrapyramidal disorder. Both incidence of akathisia were of mild intensity; one participant had a dose reduction and the other continued on the same dose.
There were no clinically significant changes from baseline at the last visit in mean fasting metabolic parameters (Table 4) F I G U R E 3 Mean (SD) change from baseline at Week 6 in SDS mean score and individual items (efficacy population). Mean scores at baseline were 6.5 for mean score (calculated as mean of three item scores), 6.7 for social life, 6.4 for family life and home responsibilities, and 6.3 for work and school life. Range 0-10, higher scores indicate greater impairment. SD, standard deviation; SDS, Sheehan Disability Scale an increase in body weight of ≥7% from baseline at Week 6; one of these participants reported weight gain as a TEAE. Mean (SD) increase in body weight from baseline (screening) at Week 6 was 1.6 (2.4) kg. One female participant had an elevated serum prolactin level at Week 6. In the ECG evaluations, two subjects had new-onset QT interval >450 ms; three subjects had increases of 30-60 ms in QT interval corrected by Bazett's formula; and two participants had increases of 30-60 ms in QT interval corrected by Fridericia's formula.
There was no worsening in mean EPS scale scores. Mean (SD) changes from baseline at the last visit were as follows: −0.2 (0.9) for SAS total score, 0 (0) for AIMS total score, and 0 (0.2) for BARS total score. Treatment-emergent suicidal behavior and ideation recorded on the C-SSRS comprised one incidence of emergence of suicidal ideation and one incidence of worsening suicidal ideation.
| DISCUSSION
In It is recognized that patients with MDD and anxiety symptoms may have more severe illness and may require a more intensive treatment approach (Wiethoff et al., 2010; Ionescu et al., 2014) . The results from this study suggest that brexpiprazole + ADT may be an appropriate treatment option for the difficult-to-treat patients with MDD and anxiety. The efficacy of brexpiprazole + ADT in treating patients with MDD and an inadequate response to ADT has previously been demonstrated in two double-blind, placebo-controlled Phase III studies (Thase et al., 2015a (Thase et al., , 2015b . Patients entered into the Phase III studies were not selected for a high level of anxiety as evidenced by mean baseline HAM-A total scores of 16-18. In these studies, reductions from baseline at Week 6 in mean HAM-A total score were greater in the 2 and 3 mg brexpiprazole + ADT groups than those in the placebo groups. In this study, mean HAM-A total score at baseline was 27, indicating a population with a high level of anxiety. Improvements in depression and anxiety symptoms were seen as early as 1 week after initiation of brexpiprazole, and followed a similar time course.
T A B L E 3 Adjunctive brexpiprazole treatment-emergent adverse events (safety population, n = 37) T A B L E 4 Mean change from baseline to last visit in fasting metabolic parameters (safety population)
Parameter
Baseline
Change from baseline at last visit Brexpiprazole was well tolerated in this population, consistent with previous studies (Thase et al., 2015a (Thase et al., , 2015b . No participants discontinued due to TEAEs or reported serious AEs during treatment with brexpiprazole + ADT. The most frequently reported TEAE was increased appetite (five participants, 13.5%). Mean weight gain over the 6-week treatment period (1.6 kg) was comparable to that reported with brexpiprazole in previous short-term studies (Thase et al., 2015a (Thase et al., , 2015b ). Brexpiprazole did not have clinically relevant adverse effects on metabolic parameters in this short-term study. The incidence of EPS-related TEAEs was low, and no worsening of EPS-related symptoms was observed using objective EPS rating scales. Few activating TEAEs were reported, with only akathisia (two participants, 5.4%) having an incidence ≥5%. This finding is clinically important since activating side effects associated with second-generation antipsychotics (Trivedi et al., 2008 ) may limit their use in an anxious population.
Overall, the tolerability profile of brexpiprazole observed in this study reflected its receptor pharmacology.
This study has several limitations, including the open-label design, lack of a placebo or active comparison group, short duration of the treatment phase, heterogeneity of ADTs, and the small number of participants. Use of low-dose benzodiazepines during the treatment period was rare; however, this may have affected the outcomes for a small number of participants. In addition, we are unable to conclude whether the improvements in anxiety symptoms were direct effects of brexpiprazole, or whether they occurred secondary to improvements in depressive symptoms.
| CONCLUSION
In conclusion, the results of this exploratory study support the effectiveness of brexpiprazole + ADT in the treatment of depression in patients with both MDD and a high level of anxiety symptoms, a newly recognized, clinically important specifier for MDD designated "Anxious Distress" by DSM-5 (American Psychiatric Association, 2013). The findings support the pivotal, double-blind, placebo-controlled studies (Thase et al., 2015a (Thase et al., , 2015b showing efficacy of brexpiprazole + ADT in the treatment of MDD in patients with an inadequate response to ADT monotherapy. Lundbeck A/S (Valby, Denmark). The sponsors were responsible for the study design, and the collection, analysis and interpretation of the data. The authors, some of whom are employed by the sponsors, were responsible for writing this manuscript and had responsibility for the decision to submit the article for publication. 
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